Colibri Enters TAVR Joint Venture With Venus Medtech Focusing On Emerging Markets
Executive Summary
US firm Colibri Heart Valve and China-based Venus Medtech have formed a venture to commercialize two heart valves in China and other emerging markets: a balloon-expandable version created by Colibri and a self-expanding version developed by Venus using tissue processed by Colibri.
You may also be interested in...
China's Venus Persists With Global TAVR Solutions Expansion
Venus Medtech, the Chinese transcatheter aortic valve technology specialist, has made its second international acquisition as it pursues its strategy for global expansion in the TAVR market.
Digital Health Roundup: Cardio Smart Watches, Pear Therapeutics Own 'Reset,' Agetech Boom
In this month’s Digital Health roundup, Medtech Insight’s Reed Miller talks about iRhythm and Withings’ smartwatches business, Barnaby Pickering reviews digital therapeutics Pear Therapeutics’ restructuring, and Marion Webb presents highlights from her new series on Agetech.
Inflation, Supply Chain Headaches And Staffing Shortages: CEOs Talk About 'Big Picture' Challenges
Although procedure volumes have mostly recovered from the shock of COVID-19 two years ago, the effects of the pandemic on the medtech sector and the economy overall will be felt for years to come. In recent analyst and sales and earnings presentations, CEOs of major medtech companies faced questions about how their company is handling these major "macro" issues.